Germán Calderillo

Dr. Germán Calderillo


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2022 in Journal of Oncology
Verified
Journal Article
Open access
PDF file
GCGermán Calderillo
Germán Calderillo
HBHoracio Lopez Basave
Horacio Lopez Basave
RRRafael Sebastian Vazquez Renteria
Rafael Sebastian Vazquez Renteria
AMAlison Castillo Morales
Alison Castillo Morales
AGAlberto Guijosa
Alberto Guijosa
WMWendy R. Muñoz-Montaño
Wendy R. Muñoz-Montaño
Background. Survival and recurrence rates following locoregional colon cancer surgical resection are highly variable. Currently used tools to assess patient risk are still imperfect. In the present work, we evaluate, for the first time, the prognostic value of the recently developed HALP (hemoglobin, albumin, lymphocyte, and platelet) index in Hispanic colon cancer patients. Patients and Methods. We conducted a retrospective cohort study in Mexican patients with a nonmetastatic colon cancer diagnosis who underwent surgical resection. We determined the preoperative HALP score optimal cut-off value by using the X-tile software. We plotted survival curves using the KaplanMeier method and performed a multivariate Cox regression analysis to explore the association of preoperative HALP score with two primary endpoints: overall survival (OS) and disease-free survival (DFS). Results. We included 640 patients (49.8 female). The optimal HALP cut-off value was 15.0. A low HALP index was statistically significantly associated with a higher TNM stage. Low HALP score was statistically significantly associated with shorter median OS in the KaplanMeier analysis (73.5 vs. 84.8 months) and in the multivariate Cox regression analysis (HR=1.942, 95 CI=1.6472.875). There was no significant association between the HALP score and DFS. Conclusions. Our findings show that the HALP index is an independent factor associated with survival in Hispanic patients, despite recurrence. It seems to reflect both the anatomical extent of the disease and traditionally unaccounted nutritional and inflammatory factors that are significant for prognosis.

1 June 2023 in International Journal of Colorectal Disease
Verified
Journal Article
Closed access
PDF file
GCGermán Calderillo
Germán Calderillo
HLHoracio Noé López-Basave
Horacio Noé López-Basave
WMWendy R. Muñoz-Montaño
Wendy R. Muñoz-Montaño
MDMaría Consuelo Díaz-Romero
María Consuelo Díaz-Romero
BCBerenice Carbajal-Lopez
Berenice Carbajal-Lopez
AAAlejandra Albarran-García
Alejandra Albarran-García

14 November 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
BCBerenice Carbajal-Lopez
Berenice Carbajal-Lopez
JCJossimar Coronel
Jossimar Coronel
MHMarytere Herrera
Marytere Herrera
Erika Ruiz-GarciaErika Ruiz-Garcia
Erika Ruiz-Garcia
SMSayako M. Miyagui-Adame
Sayako M. Miyagui-Adame
GCGermán Calderillo
Germán Calderillo
Background: The diagnosis of colorectal cancer (CRC) at early ages has become a challenging trend for oncology due to high rates of mortality worldwide. The correlation of clinical features with young-age prognosis in CRC remains unclear. Therefore, we aimed to describe the clinicopathological features and their impact on the overall survival of young Mexican adults diagnosed with CRC treated in the National Cancer Institute. Methods: This was a retrospective, observational study. The included patients were treated at the National Cancer Institute between 2004 and 2020. The statistical analyses comprised the X2 and t tests, Kaplan–Meier, log rank, and Cox regression. Statistical significances were assessed when p was bilaterally < 0.05. Results: A total of 3652 patients diagnosed with CRC attended the National Cancer Institute. Cases of early onset of CRC increased over the 16 years under study, with significant differences between the median age, from 57 in 2004 to 55 years old in 2020 (F = 5.49; gl: 12 p = 0.019). For this analysis, the population was divided in three groups: young (≤30 years), adults (31–70), and elderly (>70). The young population was mostly composed of men (62%; (n = 63), (p = 0.020), with high rates of metastatic disease (44%) (p = 0.001) and right-side tumors (57%), (p = 0.046), and with 44% with a moderate grade (p = 0.750). According to the overall survival (OS) analysis, the median OS was 29 months for young, versus 170 months for adult and 56 months for elderly patients (p <0.001, HR 1.53, 95% CI 1.11–2.10). A sub-analysis was performed considering only patients with metastatic disease. The median OS was 12 months for young, versus 17 and 9 months for adults and elderly (p = 0.08, HR 1.27, 95% CI 1.02–1.46). Conclusions: CRC diagnosis in the young population is increasing due unhealthy lifestyle habits and lack of screening. This population have clinical features of bad prognosis, such as left side, poor grade differentiation, and metastatic disease, precluding prognosis and OS.

31 August 2022 in Ciencias Psicológicas
Verified
Journal Article
Open access
PDF file
OVOscar Galindo Vázquez
Oscar Galindo Vázquez
LMLuis Alberto Mendoza-Contreras
Luis Alberto Mendoza-Contreras
JFJoel Flores-Juárez
Joel Flores-Juárez
JNJavier Núñez-Hernández
Javier Núñez-Hernández
GCGermán Calderillo
Germán Calderillo
ALABEL LERMA
ABEL LERMA
La calidad de vida es un aspecto relevante en la vida de las personas, más aún cuando se presentan comorbilidades altas en población general, por lo que su medición de forma válida y confiable es necesaria. Objetivo: Determinar las propiedades psicométricas del Instrumento de Evaluación de Funcionalidad en el Tratamiento para Enfermedades Crónicas (FACT-GP) en población general mexicana. Método: Se empleó un diseño transversal, con un muestreo no probabilístico, por disponibilidad. Análisis estadístico: Se realizó un modelo factorial confirmatorio. Resultados: Se incluyeron 254 participantes con M = 23.5 años (21-32). Se identificaron 4 factores con 18 reactivos. La consistencia interna de la escala global fue .81, que explican el 58.93 % de la varianza. El análisis factorial confirmatorio presenta índices adecuados (CFI, RMR, RMSEA), que indican un ajuste equilibrado y parsimonioso de la estructura del modelo. Conclusión: El FACT-GP mostró una estructura similar a la versión original, con indicadores válidos y confiables para su uso en la atención clínica e investigación dirigida a población general mexicana.

29 October 2024 in Cancers
Verified
Journal Article
Open access
PDF file
BCBerenice Carbajal-Lopez
Berenice Carbajal-Lopez
AGAntonio Martinez Gutierrez
Antonio Martinez Gutierrez
EMEduardo Madrigal-Santillán
Eduardo Madrigal-Santillán
GCGermán Calderillo
Germán Calderillo
JMJose A. Morales-González
Jose A. Morales-González
EPEloy Perez-Yepez
Eloy Perez-Yepez
Background/Objectives: The prognosis of colorectal cancer (CRC) is mainly based on the clinical stage; however, CRC is considered a complex disease due to its molecular heterogeneity. The development of novel biomarkers to improve patients’ diagnosis and prognosis remains fundamental. Methods: A cohort of forty-nine CRC patients from the National Cancer Institute of Mexico was included to collect clinical and miRNA expression data. The expression of a group of miRNAs was compared between CRC and non-tumoral adjacent tissues. Prognosis assessment considering each miRNA expression was tested using Kaplan–Meier survival curves and Cox regressions. Statistical significance was defined as p ≤ 0.05. Trial registration: Retrospective study No.2021/046. Results: miR-3065-5p and miR-26a-5p expression differed between non-tumoral adjacent and tumoral tissues (p = 0.02). In terms of overall survival (OS), patients with low expression of miR-3065-5p had a median OS of 70 months, while patients with high levels did not reach the median OS (p = 0.041). Male patients with low expression of this miRNA had an OS of 70 months, whereas patients with high levels did not reach the median OS (p = 0.050). Under uni-multivariate analysis, clinical stage (HR: 1.30, CI 1.23–2.30; p: 0.001) and low levels of miR-3065-5p (HR: 1.30, CI 1.23–2.30; p: 0.001) were determined as predictor factors of OS. To this end, we designed the “Prognosis miRNAs assessment in cancer” (PROMIR-C) algorithm, which integrated clinical features with miR-3065-5p expression levels. Conclusions: These findings support the clinical utility of miR-26a-5p and miR-3065-5p in the diagnosis and prognosis of CRC. PROMIR-C is a fundamental tool for clinicians in treatment decision-making, prognosis assessment, and outcome of CRC.

Verified
Journal Article
Open access
PDF file
JCJossimar Coronel
Jossimar Coronel
FIFrida Rodríguez Izquierdo
Frida Rodríguez Izquierdo
BCBerenice Carbajal-Lopez
Berenice Carbajal-Lopez
EMEduardo Madrigal-Santillán
Eduardo Madrigal-Santillán
JMJose A. Morales-González
Jose A. Morales-González
YSYesennia Sánchez-Pérez
Yesennia Sánchez-Pérez
Colorectal cancer (CRC) is one of the leading causes of mortality worldwide, with rising cases in individuals under 50 years old, classified as early-onset CRC (EO-CRC). EO-CRC is characterized by having clinical features related to a worse prognosis and outcome. This underscores the critical need for early detection biomarkers. ncRNAs emerge as potential biomarkers for diagnosis, prognosis, and treatment response in other types of cancers. Sequencing data from the NCBI Bioproject PRJNA787417 were analyzed to identify differentially expressed miRNAs in early- and late-onset colorectal cancer (EO-CRC and LO-CRC). Differential expressions were assessed with a log fold change threshold of 1 and an adjusted p-value of 0.05. Predicted mRNA targets were identified via ENCORI and analyzed for pathway enrichment using the SHINYGO algorithm. RNA-seq analysis identified a 25-ncRNA EO-CRC signature, including hsa-miR-195 (downregulated) and hsa-miR-549a (upregulated), with enrichment analyses suggesting associations with MAPK, PI3K, VEGF, and KRAS pathways commonly linked to angiogenesis, migration, and invasion. This preliminary report highlights a 25-gene deregulated signature in EO-CRC, in which hsa-miR-195 and hsa-miR-549a emerge as biomarkers of clinical relevance, regulating key genes involved in angiogenesis, migration, and invasion. Their dysregulation could contribute to the aggressive clinical features and poor outcomes observed in EO-CRC.